There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Replimune Group (REPL – Research Report), Zentalis Pharmaceuticals (ZNTL – Research Report) and Doximity (DOCS – Research Report) with bullish sentiments.
Replimune Group (REPL)
Wedbush analyst Robert Driscoll reiterated a Buy rating on Replimune Group today and set a price target of $52.00. The company’s shares closed last Tuesday at $23.63.
According to TipRanks.com, Driscoll is a 1-star analyst with an average return of -1.8% and a 36.8% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Day One Biopharmaceuticals, and Zentalis Pharmaceuticals.
Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $56.17, representing a 147.1% upside. In a report issued on May 25, SVB Securities also reiterated a Buy rating on the stock.
See the top stocks recommended by analysts >>
Zentalis Pharmaceuticals (ZNTL)
Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Zentalis Pharmaceuticals today and set a price target of $50.00. The company’s shares closed last Tuesday at $25.14.
According to TipRanks.com, Canino has 0 stars on 0-5 stars ranking scale with an average return of -28.1% and a 24.2% success rate. Canino covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Deciphera Pharmaceuticals, and Theseus Pharmaceuticals.
Currently, the analyst consensus on Zentalis Pharmaceuticals is a Strong Buy with an average price target of $52.00, representing a 103.9% upside. In a report issued on May 26, H.C. Wainwright also maintained a Buy rating on the stock with a $55.00 price target.
Doximity (DOCS)
In a report released today, Scott Berg from Needham reiterated a Buy rating on Doximity, with a price target of $45.00. The company’s shares closed last Tuesday at $34.06.
According to TipRanks.com, Berg is a 4-star analyst with an average return of 4.9% and a 50.4% success rate. Berg covers the Technology sector, focusing on stocks such as BigCommerce Holdings, SEMrush Holdings, and Global-e Online.
Currently, the analyst consensus on Doximity is a Hold with an average price target of $36.33, which is a 8.0% upside from current levels. In a report issued on May 31, SVB Securities also reiterated a Buy rating on the stock with a $47.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REPL: